Dacomitinib in Treatment-Naïve EGFR-Mutated NSCLC: Real-World Insights from India | CRSF

preview_player
Показать описание
Dr. Somnath Roy shares valuable real-world experience of using Dacomitinib in treatment-naïve EGFR-mutated advanced Non-Small Cell Lung Cancer (NSCLC) from a single center in India. Join us at the CRSF 7th annual year-end review in lung cancer to explore practical insights, treatment outcomes, and implications for future therapeutic strategies.

#Dacomitinib #EGFR #NSCLC #LungCancerResearch #RealWorldData #CRSFReview #CancerTreatment #OncologyInsights

Follow us:

Event Managed By:
Horizon Conference Management
  1. CRSF - Cancer Research and Statistic Foundation
  2. crsf
  3. cancer research
  4. oncology
  5. oncologist
  6. crsf india
Рекомендации по теме
Dacomitinib in Treatment-Naïve 0:08:23

Dacomitinib in Treatment-Naïve EGFR-Mutated NSCLC: Real-World Insights from India | CRSF

Amivantamab and lazertinib 0:02:03

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

FLAURA study: a 0:06:08

FLAURA study: a new standard of care for patients with EGFR mutated NSCLC

Options for Up-front 0:05:00

Options for Up-front Therapy in EGFR-mutant NSCLC

Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Advancing Care for 0:53:55

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies

Novel EGFR Inhibitors 0:26:27

Novel EGFR Inhibitors in the Setting of Acquired Resistance

CheckMate 722: Investigating 0:02:01

CheckMate 722: Investigating the addition of immunotherapy to chemotherapy in EGFR-Mutant NSCLC

Time for Even 0:58:24

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC

Patient Selection, Therapeutic 0:28:28

Patient Selection, Therapeutic Sequencing, & Treatment Selection in EGFR Mutation-Positive NSCLC

Management of Epidermal 0:30:22

Management of Epidermal Growth Factor Receptor (EGFR) - Mutated Non-small-cell Lung Cancer (NSCLC)

15 Years of 0:58:47

15 Years of Advances in EGFR Mutant Lung Cancer

Advances in Frontline 0:08:11

Advances in Frontline Therapy for EGFR+ NSCLC

TKI-resistant EGFR-mutant NSCLC 0:20:35

TKI-resistant EGFR-mutant NSCLC

Case 4: Treating 0:06:55

Case 4: Treating EGFR+ NSCLC After Osimertinib

Poziotinib Data in 0:05:27

Poziotinib Data in EGFR Exon 20-Mutant NSCLC

Management of EGFR-Mutant 1:18:11

Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases

Improving Outcomes in 1:02:02

Improving Outcomes in Molecularly Altered NSCLC Through Precision Testing and Treatment

Improving Outcomes in 1:02:08

Improving Outcomes in Molecularly Altered NSCLC Through Precision Testing and Treatment

Webinar: Lung Cancer 0:39:16

Webinar: Lung Cancer Clinical Trials Evaluating Efficacy and Overcoming Resistance | Veeda

NSCLC: Integrating EGFR-Inhibiting 0:37:23

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

EGFR TKI Resistance: 0:10:39

EGFR TKI Resistance: Progress and Challenges

eCME on Treatment 1:21:04

eCME on Treatment options for EGFR Mutant Advanced NSCLC

Evolution of TKIs 0:28:53

Evolution of TKIs and current treatment outcomes in 1st line EGFRm NSCLC